1. Home
  2. MUX vs CELC Comparison

MUX vs CELC Comparison

Compare MUX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

HOLD

Current Price

$20.02

Market Cap

936.8M

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$102.35

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUX
CELC
Founded
1979
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
936.8M
3.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
MUX
CELC
Price
$20.02
$102.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$21.63
$100.13
AVG Volume (30 Days)
1.2M
947.3K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$166,453,000.00
N/A
Revenue This Year
$7.70
N/A
Revenue Next Year
$29.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.38
$7.58
52 Week High
$24.88
$112.64

Technical Indicators

Market Signals
Indicator
MUX
CELC
Relative Strength Index (RSI) 61.81 60.99
Support Level $18.65 $97.27
Resistance Level $20.50 $105.14
Average True Range (ATR) 1.09 5.04
MACD 0.08 -1.29
Stochastic Oscillator 72.19 33.80

Price Performance

Historical Comparison
MUX
CELC

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: